Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The respiratory syncytial virus (RSV) prefusion F protein is a type I integral membrane fusion glycoprotein found on the surface of the RSV virion. It plays a pivotal role in viral pathogenesis by mediating the fusion of the viral envelope with host cell membranes, enabling viral entry and infection. The F protein exists in two major conformations: a metastable, lollipop-shaped prefusion form (preF) present before virus-cell interaction, and a more stable, crutch-shaped postfusion form (postF) that results after membrane fusion or spontaneous rearrangement. The prefusion conformation exposes epitopes that elicit highly potent neutralizing antibodies; these epitopes are less accessible or absent in the postfusion state, making it an optimal vaccine antigen candidate.
Vaccines induce neutralizing antibodies that bind to the prefusion F protein, preventing viral entry and infection.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Respiratory Syncytial Virus Prefusion F Protein (RSV preF).